These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32140351)

  • 1. Efficacy and Safety of Escitalopram Oral Drops to Treat Major Depressive Disorder and Generalized Anxiety Disorder in Adolescent, Adult and Geriatric Patients: A Prospective Multicenter Observational Study in Pakistan.
    Afridi MI; Dogar IA; Nizami AT; Aslam R; Mustafa AB; Syed Muhammad S; Maheshwary N
    Cureus; 2020 Jan; 12(1):e6792. PubMed ID: 32140351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.
    Wang G; You X; Wang X; Xu X; Bai L; Xie J; Yao Z; Yi Q; Ma J; Wang J; Zhuo J; Hu C
    Neuropsychiatr Dis Treat; 2018; 14():2087-2097. PubMed ID: 30147321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population.
    Jiang K; Li L; Wang X; Fang M; Shi J; Cao Q; He J; Wang J; Tan W; Hu C
    Neuropsychiatr Dis Treat; 2017; 13():515-526. PubMed ID: 28255239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder.
    Sinha S; Chary S; Thakur P; Talluri L; Reddy M; Verma KK; Saha P; Gupta VB; Ramaiah KA; Khanum SZ
    Cureus; 2021 Jul; 13(7):e16689. PubMed ID: 34513348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.
    Christensen MC; Schmidt S; Grande I
    J Psychopharmacol; 2022 May; 36(5):566-577. PubMed ID: 35499104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study].
    Schmitt L; Arbus C; Tonnoir B
    Encephale; 2006; 32(2 Pt 1):270-7. PubMed ID: 16910629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
    Demyttenaere K; Andersen HF; Reines EH
    Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.
    Gorman JM; Korotzer A; Su G
    CNS Spectr; 2002 Apr; 7(4 Suppl 1):40-4. PubMed ID: 15131492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
    Olié JP; Tonnoir B; Ménard F; Galinowski A
    Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
    J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B; Andersen HF; Dolberg OT
    Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
    Sheehan DV; Harnett-Sheehan K; Spann ME; Thompson HF; Prakash A
    Int Clin Psychopharmacol; 2011 Mar; 26(2):75-83. PubMed ID: 21102344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.